Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...
Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback